Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court rejects FDA pre-emption claims

Executive Summary

In a June 22 ruling in a case involving Wyeth's Prempro (estrogen/progestin), New Jersey Superior Court rules that FDA approval of a drug's label is insufficient to pre-empt a product liability suit claiming inadequate warning of the product's risks. The Third Circuit U.S. Court of Appeals is set to be the first appellate court to address preemption with two pending cases (1"The Pink Sheet" April 9, 2007, p. 24)...

You may also be interested in...



FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases

A federal appellate court will take up the issue of whether FDA approved labeling preempts state litigation claiming companies failed to warn of a product's risks, following years of conflicting rulings from district courts

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel